research
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib
Canada-in-Asia Conference Returns to Singapore February 19-21, 2025
VANCOUVER, British Columbia, Feb. 02, 2025 (GLOBE NEWSWIRE)
VedTechBio® Launches RxAgentAI™ – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio® Announces a Drug Discovery Collaboration with RenaissThera®
BENGALURU, India, Oct. 16, 2024 (GLOBE NEWSWIRE) — VedTechB
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstra
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Data from the phase Ib Beamion LUNG-1 trial selected for lat
New Smart Communications Report Finds Nearly 80% of Consumers Want Companies to Disclose Generative AI Use
LONDON, July 23, 2024 (GLOBE NEWSWIRE) — Smart Communicatio
London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) — London Re
AMEC Announces New Chair
LONDON, June 05, 2024 (GLOBE NEWSWIRE) — The International
【主編前言】換湯亦換藥
近兩年隨著疫後重開各口岸，博彩旅遊業復甦勢頭強勁，雖然仍未重回疫情前巔峰，但亦已回復七、八成，只是這種復甦只局限與博彩旅遊業相關的行業或地區，加上澳車北上政策吸引了大量澳門居民北上消費，一般民生區的店舖與旅遊區的店舖彷如處於平衡時空，旅遊區店舖生意有多旺，非旅遊區店舖生意有多差。
Mandy Kuok
【社長之言】我們不應安於現狀
“如何在經濟復甦過程中有效應對澳門本土經濟發展不充分、不平衡的問題？如何解決產業多元化發展與社會期待不符的問題？中小企業普遍面對且迫切的困難？在粵澳合作框架下，如何更好地利用橫琴的發展，讓其更有效地為澳門經濟發展作出貢獻？”
馬天龍